Skip to main content

Table 4 Multivariate Cox regression analyses of the overall survival and disease-free survival according to the level of γ-GT before and after PSM

From: Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization

Characteristics

OS

  

DFS

Before PSM

After PSM

Before PSM

After PSM

HR (95CI)

P-value

HR (95CI)

P-value

HR (95CI)

P-value

HR (95CI)

P-value

γ-GT ≤ 54 U/L

 Tumor number (Multiple vs Single)

2.11 (1.55–2.87)

< 0.001

1.97 (1.33–2.93)

0.001

2.07 (1.61–2.65)

< 0.001

2.18 (1.59–2.98)

< 0.001

 Tumor diameter (cm)

1.11 (1.07–1.15)

< 0.001

1.11 (1.05–1.17)

< 0.001

1.08 (1.04–1.12)

< 0.001

1.08 (1.03–1.13)

0.003

 Capsule (Absent vs Present)

1.36 (1.02–1.81)

0.039

1.41 (0.95–2.09)

0.085

–

–

–

–

 MVI (Absent vs Present)

1.58 (1.22–2.06)

0.001

1.57 (1.10–2.26)

0.014

1.44 (1.16–1.79)

0.001

1.45 (1.08–1.95)

0.014

 PA-TACE (Yes vs No)

0.85 (0.65–1.11)

0.222

0.89 (0.64–1.23)

0.471

0.86 (0.69–1.08)

0.190

0.91 (0.71–1.18)

0.483

γ-GT > 54 U/L

 TBil (μmol/L)

1.01 (1.00–1.03)

0.036

1.02 (1.01–1.04)

0.009

1.01 (1.00–1.03)

0.028

1.03 (1.01–1.05)

< 0.001

 AFP (> 400 vs 400 ng/mL)

1.71 (1.39–2.10)

< 0.001

1.71 (1.32–2.22)

< 0.001

1.43 (1.20–1.71)

< 0.001

1.47 (1.18–1.84)

0.001

 Tumor number (Multiple vs Single)

–

–

–

–

1.25 (1.01–1.56)

0.042

1.08 (0.82–1.42)

0.589

 Tumor diameter (cm)

1.06 (1.04–1.09)

< 0.001

1.07 (1.04–1.10)

< 0.001

1.03 (1.01–1.05)

0.008

1.04 (1.01–1.06)

0.005

 Capsule (Absent vs Present)

1.33 (1.05–1.68)

0.019

1.43 (1.05–1.95)

0.024

–

–

–

–

 MVI (Absent vs Present)

1.43 (1.14–1.79)

0.002

1.21 (0.89–1.64)

0.219

1.37 (1.13–1.65)

0.001

1.19 (0.92–1.54)

0.174

 PA-TACE (Yes vs No)

0.69 (0.55–0.86)

0.001

0.66 (0.52–0.85)

0.001

0.76 (0.63–0.91)

0.003

0.74 (0.60–0.92)

0.006

  1. Note: OS overall survival; DFS disease-free survival; HR hazard ratio; CI confidence interval; PSM propensity score matching; γ-GT gamma-glutamyl transferase; TBil total bilirubin; AFP alpha-fetoprotein; MVI microvascular invasion; PA-TACE postoperative adjuvant transarterial chemoembolization